Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2440 vs Perjeta in Early or Locally Advanced HER2-Positive Breast Cancer
NCT05985187Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2440 in HER2-positive breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
TQB2440
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05985187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985187.